drugset / Trial / NCT02281448

Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

NCT02281448

Phase 1 Completed 20 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

Single centre, two-way crossover, randomised, open-label study in 20 healthy female volunteers.The volunteers received an oral single-dose of a combined contraceptive containing with an oral once daily dose of 1200 mg of BIA 2-093

Timeline

Start
2005-03
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 1200 mg Oral
Subject Levonorgestrel Small molecule 150 ug Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications